Published: 28 March 2022
Author(s): M Carrier, TF Wang
Issue: June 2022
Section: Commentary

Venous thromboembolism (VTE) is a common complication among patients with cancer. The 6-month risk of VTE complication for cancer patients is 12-fold higher and as much as 23-fold higher in those receiving chemotherapy or targeted therapy when compared to patients without cancer [1]. Furthermore, the 12-month cumulative incidence for VTE has increased three-fold over the past two decades in this patient population [1]. Hence, cancer-associated thrombosis (CAT) is a frequent complication that most clinicians caring for patients with cancer must routinely manage.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.